((自动化翻译由路透提供，请见免责声明 ))
1月22日 - ** 在香港上市的乐普生物 大涨14.2%，报2.73港元；将创下自2024年12月17日以来的最大单日百分比涨幅
** 股价创2024年12月27日以来新高；有望连续第五个交易日上涨
** 公司向 ArriVent BioPharma 授予全球独家权利 (link)，在大中华地区以外开发和商业化乐普的新型抗体药物结合物候选药物 MRG007，该药物用于治疗胃肠道癌症。
** 乐普将获得一次性预付款和近期里程碑付款 470 万美元
** 有资格获得高达 11.6 亿美元的开发、监管和销售里程碑款项，以及按许可地区净销售额的高个位数至低十位数百分比收取的分级特许权使用费
** AVBP周二上涨 3.7
** 乐普去年下跌约 38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.